SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. on July 7, 2022. The registrant is a Delaware corporation with principal executive offices in Westport, Connecticut, and its common stock trades on the NASDAQ Capital Market under the symbol BSGM.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes and Events
Under Item 7.01 (Regulation FD Disclosure), the Company announced a material business development:
- Kansas City Heart Institute at Overland Park Regional Medical Center in Kansas City, U.S., has signed a purchase agreement to acquire the Company's PURE EPTM System.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management outlook, or specific risk factors beyond the standard disclaimer. The Company explicitly states it undertakes no obligation to update, supplement, or amend the materials attached to this report. The information is furnished pursuant to Regulation FD but is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the terms and closing conditions of the purchase agreement with Kansas City Heart Institute.
- Confirm the expected revenue recognition timeline for the PURE EPTM System sale.
- Review the attached Exhibit 99.1 (Press Release) for specific details on the transaction scope.